Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19007329 | 0.85 | NOS3 (0.43) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL21078890 | 0.79 | NOS3 (0.44) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL4547885 | 0.73 | NOS2 (0.61) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL28202668 | 0.70 | NOS3 (0.42) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL15980604 | 0.70 | NOS3 (0.42) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL29051972 | 0.70 | NOS3 (0.42) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL20063092 | 0.70 | NOS3 (0.42) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL20063088 | 0.70 | NOS3 (0.42) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL807733 | 0.70 | KMT2A (0.47) | NOS3NOS1NOS2CYP3A4CYP2D6 | |
| SCHEMBL803445 | 0.69 | POLB (0.38) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | NOS3 817/4885NOS1 3333/4885NOS2 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.